Bortezomib
NDC Package 72266-243-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Bortezomib is a medication used to treat certain types of cancer (such as multiple myeloma, mantle cell lymphoma). Marketed by Fosun Pharma Usa Inc, this product is identified by NDC 72266-243 and is authorized under FDA application NDA215331.

Identification & Billing

NDC Package Code
72266-243-01
Package Description
1 INJECTION in 1 VIAL, SINGLE-DOSE
Product Code
72266-243
11-Digit Billing Format
72266024301

Clinical Specifications

Proprietary Name
Bortezomib
Dosage Form
-
Usage Information
This medication is used to treat certain types of cancer (such as multiple myeloma, mantle cell lymphoma). It works by slowing or stopping the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Fosun Pharma Usa Inc
FDA Application #
NDA215331
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-23-2022
End Marketing Date
06-30-2024
Listing Expiration
06-30-2024
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72266-243-01 identifies a specific commercial package of 1 injection in 1 vial, single-dose of Bortezomib, labeled by Fosun Pharma Usa Inc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Fosun Pharma Usa Inc on August 23, 2022. The current certification is valid through June 30, 2024.

What are the primary indications for this medication?

This medication is used to treat certain types of cancer (such as multiple myeloma, mantle cell lymphoma). It works by slowing or stopping the growth of cancer cells.

How is this Fosun Pharma Usa Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72266024301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72266-243-01
11-Digit CMS (5-4-2)
72266-0243-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.